Treating rheumatoid arthritis with x-ray microbeams with and without dose enhancement with iodine or gold nanoparticles

Goal of proposed treatment are to reduce pain, decrease inflammation and improve a person's overall functioning.

Rheumatoid arthritis is a long-term autoimmune disorder, in which the cause is not yet clear, but believed to involve a combination of genetic and environmental factors. The underlying mechanism involves the body's immune system attacking the joints. The results include inflammation and thickening of the joint capsule, which affects undelying bone and cartilage. Typically this results in warm, swollen joints with pain and stiffness that often grows worse with time.

Patient undergoes a form of treatment, that include either with or without an injection. The injection is with iodine or gold nanoparticles, that are applied locally to the inflamed, painful areas. Affected areas due to RA are constantly targeted by x-ray microbeams. The microbeams process of affected areas are administered after the correct amount of time has passed for the immune cells to uptake nanoparticles. The irradiation is expected to ablate the immune cells, including the macrophages, which are assumed to be the agents causing the inflammation and its on going associated pain. The key factor of microbeam irradiation is that it it will be completely harmless to the irradiated tissues and to the subject.

Proposed technology could replace and enhance current treatement for RA, treatment is required only a few times per year and has ability to treat disorder long-term. This approach opposses current treatement of daily prescription based steriod pills.

Radiology, Stony Brook University Cancer Center, Neurology, Radiation Oncology

US Provisional Filed.

Working prototype available for demonstration.

We seek to develop and commercialize, by an exclusive or non-exclusive license agreement and/or sponsored research, with a company active in the area.

Exclusive License - All Fields

Radiation therapy, x-ray microbeams, tissue-sparing effect, immune cells, macrophages, monocytes, microglia, T-lymphocyte, B-lumphocyte, neutrophils, MHC-II expressing cells , ,

Patent Information:
Technology/Start-up ID: